| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Canaccord Genuity analyst William Plovanic maintains Insulet (NASDAQ:PODD) with a Buy and raises the price target from $399 ...
RBC Capital analyst Shagun Singh maintains Insulet (NASDAQ:PODD) with a Outperform and raises the price target from $365 to ...
Wells Fargo analyst Lawrence Biegelsen maintains Insulet (NASDAQ:PODD) with a Overweight and raises the price target from $3...
UBS analyst Matthew Taylor maintains Insulet (NASDAQ:PODD) with a Neutral and raises the price target from $320 to $355.
Truist Securities analyst Richard Newitter reiterates Insulet (NASDAQ:PODD) with a Buy and raises the price target from $365...
Barclays analyst Matt Miksic maintains Insulet (NASDAQ:PODD) with a Equal-Weight and raises the price target from $301 to $316.
Jefferies analyst Matthew Taylor maintains Insulet (NASDAQ:PODD) with a Buy and raises the price target from $375 to $400.
2025 Outlook:For the quarter and year ending December 31, 2025, the Company is providing the following guidance (revenue in con...
2025 Outlook:For the quarter and year ending December 31, 2025, the Company is providing the following guidance (revenue in con...